Heart failure & cardiomyopathies
Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction
Authors' conclusion
At current pricing, the use of quadruple therapy in patients with HFrEF was cost effective compared with triple therapy and double therapy.
Study context
- Population
- Simulated patients with heart failure with reduced ejection fraction (HFrEF) based on PARADIGM-HF trial participants
- Participants
- 1,000 simulated patients
- Comparison
- Quadruple therapy vs triple therapy vs double therapy
- Outcome
- Cost-effectiveness (incremental cost-effectiveness ratio)
Methodological details2-state Markov model, simulated populations based on PARADIGM-HF participants, US health care system perspective, 10,000 probabilistic simulations
- 2-state Markov model
- Simulated populations based on PARADIGM-HF participants
- US health care system perspective
- 10,000 probabilistic simulations
Main finding
As reported in the abstract
Incremental cost-effectiveness ratio
$81,000
Quadruple therapy vs Triple therapy
Incremental cost-effectiveness ratio
$51,081
Quadruple therapy vs Double therapy
Further findings
| Outcome | Estimate |
|---|---|
| Life-years gainedQuadruple therapy vs Triple therapy | increase 1.73 life-years |
| Life-years gainedQuadruple therapy vs Double therapy | increase 2.87 life-years |
| Quality-adjusted life-years gainedQuadruple therapy vs Triple therapy | increase 1.12 years |
| Quality-adjusted life-years gainedQuadruple therapy vs Double therapy | increase 1.85 years |
Probabilistic simulations with ICER <$150,000
- Quadruple vs triple therapy
- 91.7%
- Quadruple vs double therapy
- 99.9%
Original publication
Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. Published 1 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →